HomeCompareAKRO vs QSR

AKRO vs QSR: Dividend Comparison 2026

AKRO yields 3.66% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKRO wins by $667.00 in total portfolio value
10 years
AKRO
AKRO
● Live price
3.66%
Share price
$54.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$463.02
Full AKRO calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — AKRO vs QSR

📍 AKRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKROQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKRO + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKRO pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRO
Annual income on $10K today (after 15% tax)
$311.07/yr
After 10yr DRIP, annual income (after tax)
$393.57/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, AKRO beats the other by $63.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRO + QSR for your $10,000?

AKRO: 50%QSR: 50%
100% QSR50/50100% AKRO
Portfolio after 10yr
$25.0K
Annual income
$425.45/yr
Blended yield
1.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

AKRO
Analyst Ratings
10
Buy
4
Hold
Consensus: Buy
Price Target
$54.67
+0.0% upside vs current
Range: $54.00 — $56.00
Altman Z
54.7
Piotroski
2/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRO buys
0
QSR buys
0
No recent congressional trades found for AKRO or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKROQSR
Forward yield3.66%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$25.4K$24.7K
Annual income after 10y$463.02$387.88
Total dividends collected$4.2K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusBuyBuy
Analyst price target$54.67$81.57

Year-by-year: AKRO vs QSR ($10,000, DRIP)

YearAKRO PortfolioAKRO Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$11,066$365.97$11,038$337.57+$28.00AKRO
2$12,219$378.48$12,156$345.43+$63.00AKRO
3$13,465$390.58$13,359$352.69+$106.00AKRO
4$14,810$402.25$14,654$359.36+$156.00AKRO
5$16,260$413.48$16,045$365.45+$215.00AKRO
6$17,822$424.27$17,539$370.97+$283.00AKRO
7$19,505$434.61$19,143$375.96+$362.00AKRO
8$21,314$444.52$20,863$380.42+$451.00AKRO
9$23,260$453.99$22,708$384.39+$552.00AKRO
10$25,352$463.02$24,685$387.88+$667.00AKRO

AKRO vs QSR: Complete Analysis 2026

AKROStock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full AKRO Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this AKRO vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRO vs SCHDAKRO vs JEPIAKRO vs OAKRO vs KOAKRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.